(PharmaNewsWire.Com, June 13, 2017 ) Ischemic reperfusion injury is the tissue damage that happens when blood supply returns to the tissue after a period of lack of oxygen. The absence of oxygen and nutrients creates a condition in which the restoration of circulation results in inflammation and oxidative damage through the induction of oxidative. Symptoms include headache, bradycardia, seizures and hypertension. Risk factors include hypertension, hyperlipidemia, diabetes, insulin resistance, heart failure, altered coronary circulation, and aging.
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Ischemia Reperfusion Injury - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Ischemia Reperfusion Injury (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Ischemia Reperfusion Injury (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Ischemia Reperfusion Injury and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 4, 4, 26 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 22 and 4 molecules, respectively.
Ischemia Reperfusion Injury (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
- The pipeline guide provides a snapshot of the global therapeutic landscape of Ischemia Reperfusion Injury (Cardiovascular). - The pipeline guide reviews pipeline therapeutics for Ischemia Reperfusion Injury (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Ischemia Reperfusion Injury (Cardiovascular) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Ischemia Reperfusion Injury (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Ischemia Reperfusion Injury (Cardiovascular)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Ischemia Reperfusion Injury (Cardiovascular). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Ischemia Reperfusion Injury (Cardiovascular) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Number of Products under Development for Ischemia Reperfusion Injury, H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Products under Development by Universities/Institutes, H1 2017 Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017 Ischemia Reperfusion Injury - Pipeline by Amyndas Pharmaceuticals LLC, H1 2017 Ischemia Reperfusion Injury - Pipeline by Angion Biomedica Corp, H1 2017 Ischemia Reperfusion Injury - Pipeline by Biomedica Management Corp (Inactive), H1 2017 Ischemia Reperfusion Injury - Pipeline by Bolder Biotechnology Inc, H1 2017 Ischemia Reperfusion Injury - Pipeline by Corline Biomedical AB, H1 2017 Ischemia Reperfusion Injury - Pipeline by Curatis Pharma GmbH, H1 2017 Ischemia Reperfusion Injury - Pipeline by Erimos Pharmaceuticals LLC, H1 2017 Ischemia Reperfusion Injury - Pipeline by Hope Pharmaceuticals Inc, H1 2017 Ischemia Reperfusion Injury - Pipeline by Ischemix Inc, H1 2017 Ischemia Reperfusion Injury - Pipeline by Kowa Company Ltd, H1 2017 Ischemia Reperfusion Injury - Pipeline by NovelMed Therapeutics Inc, H1 2017 Ischemia Reperfusion Injury - Pipeline by Omeros Corp, H1 2017 Ischemia Reperfusion Injury - Pipeline by Opsona Therapeutics Ltd, H1 2017 Ischemia Reperfusion Injury - Pipeline by Orexo AB, H1 2017 Ischemia Reperfusion Injury - Pipeline by Pharming Group NV, H1 2017 Ischemia Reperfusion Injury - Pipeline by Prolong Pharmaceuticals LLC, H1 2017 Ischemia Reperfusion Injury - Pipeline by Proteo Inc, H1 2017 Ischemia Reperfusion Injury - Pipeline by Prothix BV, H1 2017 Ischemia Reperfusion Injury - Pipeline by Recordati SpA, H1 2017 Ischemia Reperfusion Injury - Pipeline by SBI Pharmaceuticals Co Ltd, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Ischemia Reperfusion Injury - Dormant Projects, H1 2017 Ischemia Reperfusion Injury - Dormant Projects, H1 2017 (Contd..1), H1 2017 Ischemia Reperfusion Injury - Dormant Projects, H1 2017 (Contd..2), H1 2017 Ischemia Reperfusion Injury - Discontinued Products, H1 2017
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
